Viridian Shares Plunge Despite Elegrobart Delivering Strong Phase 3 Results In Thyroid Eye Disease

Viridian reported positive topline Phase 3 REVEAL-1 results: Elegrobart met the primary endpoint with a highly statistically significant improvement in proptosis responder rate in patients with active thyroid eye disease. This Phase 3 success materially de-risks the program and supports a potential regulatory filing and commercialization opportunity for VRDN. Expect a meaningful stock re-rating and heightened investor focus; monitor the full data release and regulatory pathway timing.

Analysis

Viridian reported positive topline Phase 3 REVEAL-1 results: Elegrobart met the primary endpoint with a highly statistically significant improvement in proptosis responder rate in patients with active thyroid eye disease. This Phase 3 success materially de-risks the program and supports a potential regulatory filing and commercialization opportunity for VRDN. Expect a meaningful stock re-rating and heightened investor focus; monitor the full data release and regulatory pathway timing.